申请人:Abbott Laboratories
公开号:US05512581A1
公开(公告)日:1996-04-30
The present invention relates to a compound of formula W--X--Q--Y--CH(R.sup.1)--O--N.dbd.C(R.sup.2)--A--COM or a pharmaceutically acceptable salt thereof wherein W is optionally substituted aryl or heteroaryl; X is a valence bond, or methylene, divalent alkylene, alkenylene, alkynylene or alkyloxy; Q is a valence bond, or --O--, --S--, >NR.sup.4 or >NCOR.sup.5 ; Y is optionally substituted phenyl, biphenyl, naphthyl, tetrahydronaphthyl, indolyl, pyridyl, or benzo b!thienyl, thienyl, thiazolyl, or thiazolylphenyl; R.sup.1 is alkyl, cycloalkyl, alkoxyalkyl, aryl or arylalkyl, heteroaryl or heteroarylalkyl; R.sup.2 is hydrogen, alkyl or hydroxyalkyl; A is a valence bond or is selected from alkylene, alkenylene, alkynylene, cycloalkylene, phenylene, pyridylene, thienylene and furylene; and M is a pharmaceutically acceptable, metabolically cleavable group, --OR.sup.6, --NR.sup.6 R.sup.7, --NH-tetrazoyl, --NH-2-, 3-, or 4-pyridyl, and --NH-2-, 4-, or 5-thiazolyl which inhibit leukotriene biosynthesis and are useful in the treatment of inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method for inhibiting lipoxygenase activity and leukotriene biosynthesis.
本发明涉及一种化合物,其化学式为W--X--Q--Y--CH(R.sup.1)--O--N.dbd.C(R.sup.2)--A--COM或其药学上可接受的盐,其中W是可选择取代的芳基或杂环芳基;X是一个价键,或亚甲基,二价烷基,烯烃基,炔烃基或烷氧基;Q是一个价键,或--O--,--S--,>NR.sup.4或>NCOR.sup.5;Y是可选择取代的苯基,联苯基,萘基,四氢萘基,吲哚基,吡啶基,苯并噻吩基,噻吩基,噻唑基或噻唑基苯基;R.sup.1是烷基,环烷基,烷氧基烷基,芳基或芳基烷基,杂环芳基或杂环芳基烷基;R.sup.2是氢,烷基或羟基烷基;A是一个价键或选自烷基,烯烃基,炔烃基,环烷基,苯基,吡啶基,噻吩基和呋喃基;M是一种药学上可接受的、代谢可裂解的基团,--OR.sup.6,--NR.sup.6 R.sup.7,--NH-四唑基,--NH-2-, 3-或4-吡啶基,和--NH-2-, 4-或5-噻唑基,其抑制白三烯生物合成,在治疗炎症性疾病状态中有用。还公开了抑制白三烯生物合成的组合物和一种抑制脂氧合酶活性和白三烯生物合成的方法。